Evidence map›Paper›PMID 42732514›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Cryopreservation of Platelets.

Denese C Marks, Lacey Johnson

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Denese C MarksResearch and Development, Australian Red Cross Lifeblood, Sydney, NSW, Australia. dmarks@redcrossblood.org.au.
Lacey JohnsonResearch and Development, Australian Red Cross Lifeblood, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelets are transfused to stop bleeding from trauma or during surgery, and to prevent bleeding that may occur in various diseases, including cancer, bone marrow failure, and chronic blood disorders due to low or dysfunctional platelets. The platelet supply is often unpredictable, leading to shortages in hospitals, blood centers, and the military. Cryopreservation offers a solution by extending platelet shelf-life and enabling stockpiling for emergencies, rare donor phenotypes, and use in remote locations. In this chapter, cryopreservation of platelets below -65°C using 5%-6% DMSO with reconstitution of thawed platelets in plasma is described. The procedure requires standard blood banking equipment and a -80°C freezer. Platelets are stored in a -80°C freezer, as liquid nitrogen storage is impractical. Cryopreserved platelets remain viable for up to 12 years when stored below -65°C. Thawing is straightforward, though resuspension in plasma or saline is required, and the shelf life after thawing is limited to 4-8 h.

Indexed as

Blood PlateletsBlood PreservationCryopreservationBlood BankingCell SurvivalCryoprotective AgentsDimethyl SulfoxideHumansPlatelet TransfusionCryoprotective AgentsDimethyl SulfoxideCryopreservationPlateletsTransfusion

Identifiers

PMID42732514

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.